Laboratory Investigation
United States and Canadian Academy of Pathology The United States and Canadian Academy of Pathology
LWW Lippincott Williams and Wilkins
publishes Laboratory Investigation
--
                                      View Future Titles
Through Mar 2001
       Archives
Aug 1965 - Feb 2001
       Search Articles
Aug 1965 - Feb 2001
       Browse by Subject
Aug 1965 - Feb 2001
                      
Instructions to authors

Subscriptions

About the journal
   
  Sequencing Analysis of RNA and DNA of Exons 1 through 11 Shows p53 Gene Alterations To Be Present in Almost 100% of Head and Neck Squamous Cell Cancers
 
Editorial board

Email alerts

'Net Tips

Help

Feedback

Guestbook








  Arvid Kropveld, Erik. H. Rozemuller, Fredriek G.J. Leppers, Karin C. Scheidel, Roel A. de Weger, Ron Koole, Gerrit J. Hordijk, Pieter J. Slootweg, and Marcel G.J. Tilanus 
   
  Departments of Otorhinolaryngology (AK, GJH), Pathology (EHR, FGJL, KCS, RAdW, PJS, MGJT), and Maxillofacial Surgery (RK) University Hospital Utrecht, Utrecht, The Netherlands. 
   
 

Data on p53 alterations in human cancers are mainly based on studies restricted to the core domain (exons 5-9), because mutations outside this region are assumed to be rare. To test this assumption, we studied 25 consecutive patients with primary, untreated head and neck squamous cell carcinoma (HNSCC) with a p53 mutation analysis strategy that consists of sequencing all 11 p53 exons and the complete p53 mRNA. With this method, we encountered p53 mutations in 91% of patients; 33% of these were located outside the core domain. Overexpression of the p53 protein was assessed with staining with antibody Bp 53-1. Protein overexpression was found in 64%. In one case, p53 overexpression occurred without p53 gene mutations. Analysis of tumor tissue from two autopsied patients with multiple lesions in the head and neck and at distant sites allowed analysis of the clonal relationship of the different tumor foci. In one patient, the head and neck lesion had a mutation different from the one observed at the distant sites, suggesting two different primary tumors, one of them leading to widespread metastastic disease. In all lesions from the second patient, the same mutation was found, suggesting one primary that had metastatized. It appears that sequencing of all exons of the p53 gene is vital for assessment of the real incidence of p53 mutations in HNSCC, because 33% of all mutations are located outside the core domain, leading to a mutation frequency of almost 100 in HNSCC. In 96% of cases, either presence or absence of p53 protein expression could be explained by the type of p53 gene mutation. When only analyzing the p53 core domain, the incidence of p53 mutations in HNSCC is underestimated. (Lab Invest 1999, 79:347-353).